<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00248521</url>
  </required_header>
  <id_info>
    <org_study_id>ICR-PH1/102</org_study_id>
    <secondary_id>CDR0000442402</secondary_id>
    <secondary_id>NCI-6547</secondary_id>
    <nct_id>NCT00248521</nct_id>
  </id_info>
  <brief_title>17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Treating Patients With Metastatic Solid Tumors or Tumors That Cannot Be Removed By Surgery</brief_title>
  <official_title>A Cancer Research UK Phase I Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of 17-Dimethylaminoethyl-amino-17-Demethoxygeldanamycin (17-DMAG) Given as a Once Weekly Infusion in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as&#xD;
      17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of 17-DMAG in treating&#xD;
      patients with metastatic solid tumors or tumors that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose, dose-limiting toxicity, and recommended phase II&#xD;
           dose of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in patients with&#xD;
           unresectable or metastatic solid tumors.&#xD;
&#xD;
        -  Determine the feasibility, safety, and toxicity profile of this drug in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the clinical pharmacokinetic profile of this drug in these patients.&#xD;
&#xD;
        -  Determine tumor response in patients treated with this drug.&#xD;
&#xD;
        -  Determine the biologically effective dose.&#xD;
&#xD;
      OUTLINE: This is an open-label, non-randomized, dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) IV over 1 hour&#xD;
      on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of 17-DMAG until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity. An additional 10 patients are treated at the MTD.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 28 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 25-35 patients will be accrued for this study within 12-18&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2005</start_date>
  <primary_completion_date type="Anticipated">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended phase II dose of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) at 28 days after treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heat shock protein 90 (HSP90) client protein and co-chaperone changes up to 29 days after treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response by RECIST criteria every 6 weeks while on study</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pharmacokinetic profile established during the first course of treatment</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvespimycin hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed solid tumor&#xD;
&#xD;
               -  Unresectable or metastatic disease&#xD;
&#xD;
          -  Standard curative or palliative measures do not exist OR are no longer effective OR&#xD;
             patient refused such measures&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  ALT and AST ≤ 1.5 times upper limit of normal&#xD;
&#xD;
          -  No chronic liver disease&#xD;
&#xD;
          -  Hepatitis B or C negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance normal&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic New York Heart Association class III-IV cardiac disease&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No active ischemic heart disease within the past year&#xD;
&#xD;
          -  No poorly controlled angina&#xD;
&#xD;
          -  No uncontrolled dysrhythmia or dysrhythmias requiring antiarrhythmic drugs&#xD;
&#xD;
          -  No transient ischemic attack&#xD;
&#xD;
          -  No stroke&#xD;
&#xD;
          -  No peripheral vascular disease&#xD;
&#xD;
          -  No congenital long QT syndrome&#xD;
&#xD;
          -  No history of serious ventricular arrhythmia (ventricular tachycardia or ventricular&#xD;
             fibrillation ≥ 3 beats in a row)&#xD;
&#xD;
          -  QTc &lt; 450 msec (for men) and 470 msec (for woman)&#xD;
&#xD;
          -  LVEF &gt; 40% by MUGA&#xD;
&#xD;
          -  No left bundle branch block&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No symptomatic pulmonary disease requiring medication, including any of the following:&#xD;
&#xD;
               -  Dyspnea with or without exertion&#xD;
&#xD;
               -  Paroxysmal nocturnal dyspnea&#xD;
&#xD;
               -  Oxygen requirement&#xD;
&#xD;
               -  Significant pulmonary disease (e.g., chronic obstructive/restrictive pulmonary&#xD;
                  disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception 4 weeks before, during, and for 6&#xD;
             months after completion of study treatment&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated cone biopsied&#xD;
             carcinoma in situ of the cervix or basal cell or squamous cell skin cancer&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No diabetes mellitus (with evidence of severe peripheral vascular disease or ulcers)&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  Concurrent epoetin alfa allowed&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  No prior 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 4 weeks since prior endocrine therapy&#xD;
&#xD;
          -  Concurrent luteinizing hormone-releasing hormone analogues for androgen-insensitive&#xD;
             prostate cancer and rising prostate-specific antigen allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy (except for palliative treatment)&#xD;
&#xD;
          -  No prior irradiation field that potentially included the heart (e.g., mantle)&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed&#xD;
&#xD;
          -  At least 5 half-lives since prior and no concurrent medication that prolong QTc&#xD;
&#xD;
          -  No other concurrent anticancer or investigational agents&#xD;
&#xD;
          -  No concurrent grapefruit juice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian R. Judson, MA, MD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Cancer Research, United Kingdom</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Cancer Research - Sutton</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital Trust Incorporating Belvoir Park Hospital</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT8 8JR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Pacey SC, Wilson RH, Walton M, et al.: A phase I trial of the heat shock protein 90 (HSP90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly, intravenously, to patients with advanced solid tumors. [Abstract] American Association for Cancer Research: Molecular Targets and Cancer Therapeutics, October 22-26, 2007, San Francisco, CA A-PR-6, 2007.</citation>
  </results_reference>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>November 3, 2005</study_first_submitted>
  <study_first_submitted_qc>November 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2005</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

